Results 31 to 40 of about 30,227 (301)

Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor.

American Journal of Physiology. Endocrinology and Metabolism, 2019
Bromocriptine, a dopamine D2 receptor agonist originally used for the treatment of hyperprolactinemia, is largely successful in reducing hyperglycemia and improving glucose tolerance in type 2 diabetics.
Sarah N. Framnes-DeBoer, Ellen Bakke, Suma Yalamanchili, Hannah Peterson, D. Sandoval, R. Seeley, Deanna M. Arble   +6 more
semanticscholar   +1 more source

Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine

iScience, 2022
Summary: Bromocriptine is approved as a diabetes therapy, yet its therapeutic mechanisms remain unclear. Though bromocriptine’s actions have been mainly attributed to the stimulation of brain dopamine D2 receptors (D2R), bromocriptine also targets the ...
Despoina Aslanoglou, Suzanne Bertera, Laura Friggeri, Marta Sánchez-Soto, Jeongkyung Lee, Xiangning Xue, Ryan W. Logan, J. Robert Lane, Vijay K. Yechoor, Peter J. McCormick, Jens Meiler, R. Benjamin Free, David R. Sibley, Rita Bottino, Zachary Freyberg   +14 more
doaj  

An approach for identifying brainstem dopaminergic pathways using resting state functional MRI. [PDF]

, 2014
Here, we present an approach for identifying brainstem dopaminergic pathways using resting state functional MRI. In a group of healthy individuals, we searched for significant functional connectivity between dopamine-rich midbrain areas (substantia nigra;
D'Esposito, Mark, Kayser, Andrew, Miyakawa, Asako, Vytlacil, Jason   +3 more
core   +3 more sources

The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the BRO‐HF retrospective cohort study

ESC Heart Failure, 2018
Bromocriptine is thought to facilitate left ventricular (LV) recovery in peripartum cardiomyopathy (PPCM) through inhibition of prolactin secretion. However, this potential therapeutic effect remains controversial and was incompletely studied in diverse ...
M. Tremblay-Gravel, G. Marquis-Gravel, Robert Avram, O. Desplantie, A. Ducharme, L. Bibas, C. Pacheco, É. Couture, F. Simard, A. Poulin, I. Malhamé, D. Tran, E. Rey, F. Tournoux, L. Harvey, M. Sénéchal, Pierre Bélisle, L. Descarries, P. Farand, N. Pranno, A. Diaz, J. Afilalo, H. Ly, A. Fortier, E. Jolicoeur   +24 more
semanticscholar   +1 more source

The Effect of Pretreatment with the Hydroalcoholic Extract of Ginger on the Modulation of Dopamine D2 Receptor Agonist and Antagonist Impacts on Pain Sensitivity in Male Rats

Herbal Medicines Journal, 2022
Background and Aim: Zingiber officinale (ginger) extract increased dopamine concentration in various brain areas. Therefore, the present study aimed to investigate how ginger extract can affect the efficiency of D2 receptor agonist (bromocriptine) and ...
Mohammad Hossein Faraji, Mahnaz Taherianfard *   +1 more
doaj   +1 more source

Peripartum cardiomyopathy: diagnosis and management [PDF]

, 2017
No abstract ...
Coats, Caroline J., Dalzell, Jonathan R., Jackson, Alice M., Jhund, Pardeep S., Petrie, Mark C., Walker, Niki L.   +5 more
core   +1 more source

Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction

Clinical Research in Cardiology, 2018
BackgroundRight ventricular (RV) dysfunction predicts adverse outcome in peripartum cardiomyopathy (PPCM). We recently demonstrated beneficial effects associated with the prolactin release inhibitor bromocriptine at different doses when added to standard
A. Haghikia, J. Schwab, J. Vogel-Claussen, D. Berliner, T. Pfeffer, T. König, C. Zwadlo, V. Moulig, A. Franke, Marziel Schwarzkopf, P. Ehlermann, R. Pfister, G. Michels, R. Westenfeld, V. Stangl, U. Kühl, E. Podewski, I. Kindermann, M. Böhm, K. Sliwa, D. Hilfiker-Kleiner, J. Bauersachs   +21 more
semanticscholar   +1 more source

Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus

Endocrinology, Diabetes & Metabolism, 2020
Objective Sympathetic nervous system (SNS) overactivity is a risk factor for insulin resistance and cardiovascular disease (CVD). We evaluated the impact of bromocriptine‐QR, a dopamine‐agonist antidiabetes medication, on elevated resting heart rate (RHR)
Bindu Chamarthi, Aaron Vinik, Michael Ezrokhi, Anthony H. Cincotta   +3 more
doaj   +1 more source

Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes

BMC Pharmacology and Toxicology, 2021
Background Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia.
Mohammed Ahmed Fouad Shalaby, Hekma A. Abd El Latif, Mohamed El Yamani, May Ahmed Galal, Sherifa Kamal, Ikhlas Sindi, Raneem Masaood   +6 more
doaj   +1 more source

Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer

Molecular Cancer Therapeutics, 2018
Docetaxel resistance remains a major obstacle in the treatment of prostate cancer bone metastasis. In this study, we demonstrate that the dopamine D2 receptor (DRD2) agonist bromocriptine effectively enhances docetaxel efficacy and suppresses skeletal ...
Yang Yang, K. Mamouni, Xin Li, Yanhua Chen, S. Kavuri, Yuhong Du, H. Fu, O. Kucuk, Daqing Wu   +8 more
semanticscholar   +1 more source